Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer

The addition of a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor to endocrine therapy augments biological response in breast cancer. This phase III randomized, double-blind study evaluated the efficacy of adding palbociclib to neoadjuvant endocrine therapy (NET) for operable, hormone receptor-positive human epidermal growth factor receptor-2 (HER2)-negative breast cancer. Patients randomly received 16 weeks of endocrine therapy (letrozole for post-menopausal and tamoxifen plus ovarian function suppression for pre/peri-menopausal patients) plus palbociclib or placebo. The co-primary endpoints included preoperative endocrine prognostic index (PEPI) score and EndoPredict (EP)clin Risk Score according to the gatekeeping procedure. Of 141 randomized patients, 130 completed the treatment with surgical samples evaluable for endpoints in 126 patients. The proportion of patients with a low, moderate, and high PEPI score was 15.2%, 50.0% and 34.8% in the palbociclib arm and 13.3%, 55.0% and 31.7% in the placebo arm, respectively, with no statistical difference (one-sided p = 0.563). Statistical analysis was not performed on EPclin Risk Score. No new safety signals were reported. Permanent treatment discontinuation by adverse events was reported for 7 (9.7%) and 0 patients in the palbociclib and placebo arm, respectively. In conclusion, the addition of palbociclib to NET did not improve the efficacy.